Project 2: TOPK/PRPK as Novel Targets for Skin Cancer Prevention

Information

  • Research Project
  • 10252870
  • ApplicationId
    10252870
  • Core Project Number
    P01CA229112
  • Full Project Number
    5P01CA229112-03
  • Serial Number
    229112
  • FOA Number
    PAR-18-290
  • Sub Project Id
    7744
  • Project Start Date
    9/10/2019 - 4 years ago
  • Project End Date
    8/31/2024 - 3 months from now
  • Program Officer Name
  • Budget Start Date
    9/1/2021 - 2 years ago
  • Budget End Date
    8/31/2022 - a year ago
  • Fiscal Year
    2021
  • Support Year
    03
  • Suffix
  • Award Notice Date
    8/25/2021 - 2 years ago
Organizations

Project 2: TOPK/PRPK as Novel Targets for Skin Cancer Prevention

ABSTRACT Project 2 (Dong, Bode) TOPK/PRPK as Novel Targets for Skin Cancer Prevention Solar ultraviolet (sUV) light is an environmental carcinogen that causes inflammation and cancer. Notably, the incidence of non-melanoma skin cancer (NMSC) is increasing yearly. Reducing the incidence of cutaneous squamous cell carcinomas (cSCCs) would not only reduce their potentially severe morbidity and mortality, but also dramatically reduce the multibillion dollar health bill associated with surgical and medical treatments required for NMSCs. Thus identifying the signaling molecules in the development of cSCC is critically important. We recently discovered 2 new very promising protein targets for preventing sUV-induced skin cancer and will focus on those kinases in this renewal working with Projects 1 and 3. The T-LAK cell-originated protein kinase (TOPK), a serine-threonine kinase, is a member of the mitogen-activated protein kinase kinase (MAPKK) family, and is involved in tumor development, growth, apoptosis, and inflammation. TOPK is highly expressed in a variety of cancers, including NMSCs and melanoma. We also found that p53-related protein kinase (PRPK), which is downstream of TOPK, is a crucial player in skin cancer development. This project is aimed to examine the role of TOPK and PRPK in SSL-induced skin cancer and to test the effectiveness of novel TOPK and PRPK inhibitors in preventing sUV-induced skin cancer. The hypothesis to be tested in this proposal is that TOPK and PRPK play functional roles in SSL-induced skin carcinogenesis and are novel diagnostic markers and important targets for the development of therapeutic agents to prevent and treat NMSCs. Because our preliminary data showed that targeting TOPK or PRPK can almost totally block solar UV-induced skin cancer, we expect that data from this project have the potential to completely negate the idea that skin cancer cannot be prevented.

IC Name
NATIONAL CANCER INSTITUTE
  • Activity
    P01
  • Administering IC
    CA
  • Application Type
    5
  • Direct Cost Amount
    110775
  • Indirect Cost Amount
    49560
  • Total Cost
  • Sub Project Total Cost
    160335
  • ARRA Funded
    False
  • CFDA Code
  • Ed Inst. Type
  • Funding ICs
    NCI:160335\
  • Funding Mechanism
    Non-SBIR/STTR RPGs
  • Study Section
    ZCA1
  • Study Section Name
    Special Emphasis Panel
  • Organization Name
    UNIVERSITY OF ARIZONA
  • Organization Department
  • Organization DUNS
    806345617
  • Organization City
    TUCSON
  • Organization State
    AZ
  • Organization Country
    UNITED STATES
  • Organization Zip Code
    857210158
  • Organization District
    UNITED STATES